Safety and efficacy of leflunomide in primary Sjögren's syndrome: A phase II pilot study

Annals of the Rheumatic Diseases

Volumn 66, Issue 8, 2007, Pages 1026-1032

  Van Woerkom, J M ^a   Kruize, A A ^a   Geenen, R ^b   Van Roon, E N ^c   Goldschmeding, R ^a   Verstappen, S M M ^a   Van Roon, J A G ^a   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; LEFLUNOMIDE;

ALCOHOL INTOLERANCE; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; LUPUS LIKE SYNDROME; MOUTH ULCER; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SJOEGREN SYNDROME; SKIN MANIFESTATION; STATISTICAL ANALYSIS; TASTE DISORDER; VASCULITIS;

ADULT; ANILINE COMPOUNDS; DIARRHEA; FACIAL DERMATOSES; FATIGUE; FEMALE; HUMANS; HYDROXYBUTYRATES; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PILOT PROJECTS; SJOGREN'S SYNDROME; STATISTICS, NONPARAMETRIC; VASCULITIS;

EID: 34547213362     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.060905     Document Type: Article

References (41)

1. Valtysdottir ST, Gudbjornsson B, Hallgren R, Hetta J. Psychological well-being in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2000,18, 597-600.
2. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52, 360-4.
3. Kruize AA, Hene RJ, Vianen ME, Lafeber FP, Bijlsma JW. Systemic treatment of patients with Sjögren's syndrome: not with sulfasalazine [thesis]. Utrecht: Utrecht University, 1997;81-90, .
4. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50, 1270-6.
5. Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 1998;25, 896-9.
6. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50, 2240-5.
7. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998;18, 255-62.
8. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 1996;14, 555-8.
9. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31, 96-101.
10. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994;152, 5532-9.
11. Hagiwara E, Pando J, Ishigatsubo Y, Klinman DM. Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjogren's syndrome. J Rheumatol 1998;25, 89-93.
12. van Woerkom JM, Kruize AA, Wenting-van Wijk MJ, Knol E, Bihari IC, Jacobs JWG, et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared to non-Sjogren's sicca syndrome. Ann Rheum Dis 2005;64:1474-9.
13. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 1998;53, 20-6.
14. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165, 5962-9.
15. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61, 635-42.
16. Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 2002;169, 3392-9.
17. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159, 2542-50.
18. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44, 1984-92.
19. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39, 655-5.
20. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, et al. Improved functional ability in patients with rheumatoid arthritis - longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001;28, 1983-91.
21. Scott DL, Smolen JS, Kalden JR, van de Putte LBA, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60, 913-3.
22. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50, 1939-50.
23. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001;10, 480-3.
24. Tam LS, Li EK, Wong CK, Lam CWK, Szeto C-C. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004;13, 601-4.
25. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004;43, 315-20.
26. Talip F, Walker N, Khan W, Zimmermann B. Treatment of Felly's syndrome with leflunomide. J Rheumatol 2001;28, 868-870.
27. Cefle A. Leflunomide and azathioprine combination in refractory adult-onset Still's disease. Ann Pharmacother 2005;39, 764-7.
28. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61, 554-8.
29. Smets EM, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39, 315-25.
30. Zung WW, Broadhead WE, Roth ME. Prevalence of depressive symptoms in primary care. J Fam Prad 1993;37, 337-44.
31. van der Zee K, Sanderman R, Heyink J, de Haes H. Psychometric qualities of the RAND 36-item Health Survey 1. 0: a multidimensional measure of general health, Int J Behav Med 1996;3, 104-22.
32. Ware J, Kosinski M, Keller S. Physical and mental health suary scales - a user's manual. Boston, MA: New England Medical Center, The Health Institute, 1994.
33. van Roon EN, Yska JP, Raemaekers J, Jansen TL, van Wanrooy M, Brouwers JR. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy. J Pharm Biomed Anal 2004;36, 17-22.
34. Pillemer SR, Brennan MT, Sankar V, Leakan RA, Smith JA, Grisius M, et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo lor Sjogren's syndrome. Arthritis Rheum 2004;51, 601-4.
35. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64, 569-74.
36. Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005;64, 153-5.
37. Goeb V, Berthelot JM, Joly P, Mejjad O, de Quatrebarbes J, Reynaud-Hautin C, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2005;44, 823-4.
38. Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BAC, Tak PP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004;63, 1056-61.
39. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of antiarthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res 2004;53, 544-50.
40. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005;64, 958-60.
41. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52, 2740-50.